MedTrace Logo

A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients

NCT07690319 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 186

Last updated 2026-07-08

No results posted yet for this study

Summary

The aim of this study is to evaluate the effectiveness of early treatment with secukinumab in patients with moderate-to-severe hidradenitis suppurativa (HS) and assess its impact on disease progression using data from multiple European data sources. All data will be sourced from existing non-interventional study primary data collection, registries, and hospital cohorts that captured information collected in routine clinical practice, prior to and independent of this study.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-15
Primary Completion
2027-03-15
Completion
2027-03-15

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07690319 on ClinicalTrials.gov